Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscription Services
Promote Your Event
Submission Forms
Place an Ad
Weather
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Items For Sale
Jobs
Pets
Auctions, Estate & Garage Sales
Place an ad
Services
Community
Personals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Axsome Therapeutics, Inc.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
January 31, 2023
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022
December 07, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
November 28, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
November 09, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
October 27, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
October 21, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
October 20, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
October 10, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 03, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
September 29, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 28, 2022
From
Axsome Therapeutics, Inc.
Via
Globe NewsWire
Tickers
AXSM
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.